Adverse event rates in clinical trials aren't just percentages-they need to account for time on treatment. Learn how the FDA now requires exposure-adjusted methods like EAIR to reveal true safety risks, and why raw percentages can mislead.
Read MoreBy Warren Howard | 14 Comments | February 27, 2026
Adverse event rates in clinical trials aren't just percentages-they need to account for time on treatment. Learn how the FDA now requires exposure-adjusted methods like EAIR to reveal true safety risks, and why raw percentages can mislead.
Read MoreDiscover why side effects cause half of patients to stop their meds. Learn proven strategies to manage symptoms, improve medication adherence, and stay on track with expert advice.
Canada and the U.S. handle generic drugs differently: Canada uses centralized pricing to control costs and prevent shortages, while the U.S. relies on market competition for lower prices - but with more supply risks.
A concise guide comparing Zetia (ezetimibe) with statins, PCSK9 inhibitors, bile‑acid sequestrants and niacin, covering mechanisms, efficacy, safety and cost.
Osteoarthritis isn't just aging-it's a treatable joint disease. Learn how cartilage breaks down, why movement helps more than rest, and the four science-backed strategies that actually reduce pain and improve mobility.
A practical guide comparing Voveran with common pain‑relief alternatives, covering effectiveness, safety, cost, and tips for choosing the right option.